These results demonstrate the correlation between tumor glutamine metabolism and antitumor immunity and suggest that the combined targeting of glutamine metabolism and PD-L1 is a promising therapeutic approach that can significantly enhance the antitumor effect. This evidence concerns the gene CD274 and neoplasm.